Nuo Therapeutics, Inc.
Nuo Therapeutics is a commercial-stage medical device company focused on developing and marketing chronic wound care products, primarily in the U.S. Its principal offices are in Houston, Texas. Its main commercial offering is the Aurix System, a point-of-care technology that processes a patient’s own blood into platelet-rich plasma gel for wound management. The system includes the Aurix Wound Dressing Kit, Aurix Reagent Kit and Aurix System Centrifuge II, and is cleared for use on exuding wounds including leg ulcers, pressure ulcers and diabetic ulcers. Nuo sells branded Aurix to hospitals, wound care clinics and physicians, and sells a private-label version to Smith+Nephew, which is its exclusive U.S. distributor for that product. Smith+Nephew purchases the product from Nuo, which manufactures, packages and ships it. Nuo also works with third-party representatives and sales agents to distribute its branded product.
No SEC Form 4 filings for $AURX in the last 30 days.
See all $AURX insider activity →Nuo Therapeutics reported 3Q 2026 revenue of $1.87M, up 81% YoY, with a net loss of $424.93K. Gross margin improved to 64% from 61%. Growth was driven by increased sales of Aurix and Smith+Nephew products, though Aurix faced a temporary supply disruption. The company received a $250,000 milestone payment for expanded reimbursement coverage.
Nuo Therapeutics (AURX) closed a $325,000 second funding round, issuing 12% secured notes due 2028 and warrants. Total proceeds under the facility reached $2,000,000. The amendment allowed four new lenders, including a director, to join without increasing warrant coverage. The funds were secured to accelerate the second closing date and add lenders for liquidity.
Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Effective as of September 30, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Consent and Extension (the “Extension”) to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the “Loan Agreement”
Over the past 7 days, AlphAI's AI scored 1 news story mentioning AURX (Nuo Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent AURX coverage spans earnings, corporate actions and financial news.
The earnings beat on revenue growth may lift the stock modestly.
The new funding improves liquidity but the small amount limits market impact.
The financing provides needed capital but is small; limited immediate price impact.
The filing combines accelerating sales momentum with improved operating loss and additional near-term liquidity, while highlighting Medicare reimbursement rulemaking that could support demand.
The announcement of a distribution agreement with Smith+Nephew is positive for Nuo Therapeutics, potentially enhancing sales channels and revenue streams.
AlphAI scores every news story that mentions AURX with an AI model for sentiment and relevance, and aggregates insider trades from Nuo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nuo Therapeutics reported 3Q 2026 revenue of $1.87M, up 81% YoY, with a net loss of $424.93K. Gross margin improved to 64% from 61%. Growth was driven by increased sales of Aurix and Smith+Nephew products, though Aurix faced a temporary supply disruption. The company received a $250,000 milestone payment for expanded reimbursement coverage.
Nuo Therapeutics (AURX) closed a $325,000 second funding round, issuing 12% secured notes due 2028 and warrants. Total proceeds under the facility reached $2,000,000. The amendment allowed four new lenders, including a director, to join without increasing warrant coverage. The funds were secured to accelerate the second closing date and add lenders for liquidity.
Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Effective as of September 30, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Consent and Extension (the “Extension”) to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the “Loan Agreement”
Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99 8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633 NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth Houston, TX – August 17, 2026
HOUSTON, April 29, 2025 ( GLOBE NEWSWIRE ) -- Nuo Therapeutics, Inc. ( OTCQB: AURX ) ( "Nuo" ) , a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an ...
